Free Trial

Harrow, Inc. (NASDAQ:HROW) Given Average Recommendation of "Buy" by Brokerages

Harrow logo with Medical background

Shares of Harrow, Inc. (NASDAQ:HROW - Get Free Report) have earned an average rating of "Buy" from the six analysts that are presently covering the company, MarketBeat reports. Six research analysts have rated the stock with a buy rating. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $61.40.

HROW has been the subject of a number of research reports. BTIG Research initiated coverage on shares of Harrow in a research report on Thursday, June 12th. They set a "buy" rating and a $62.00 price target for the company. HC Wainwright lifted their price objective on Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a research report on Monday, May 12th. William Blair initiated coverage on Harrow in a research report on Tuesday, June 10th. They set an "outperform" rating for the company. Finally, B. Riley cut their price objective on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st.

Read Our Latest Research Report on Harrow

Institutional Investors Weigh In On Harrow

Several hedge funds have recently made changes to their positions in HROW. GF Fund Management CO. LTD. acquired a new stake in shares of Harrow during the fourth quarter worth $25,000. Quarry LP acquired a new stake in shares of Harrow during the first quarter worth $32,000. Tower Research Capital LLC TRC boosted its holdings in shares of Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock worth $55,000 after purchasing an additional 1,462 shares during the last quarter. Aquatic Capital Management LLC acquired a new stake in shares of Harrow during the fourth quarter worth $78,000. Finally, State of Wyoming acquired a new stake in shares of Harrow during the first quarter worth $97,000. Institutional investors and hedge funds own 72.76% of the company's stock.

Harrow Price Performance

HROW stock opened at $31.78 on Monday. The firm has a 50 day moving average of $28.32 and a 200-day moving average of $28.82. Harrow has a 12-month low of $20.85 and a 12-month high of $59.23. The company has a current ratio of 0.91, a quick ratio of 0.85 and a debt-to-equity ratio of 2.01. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -56.75 and a beta of 0.41.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.40). Harrow had a negative net margin of 10.19% and a negative return on equity of 25.01%. The company had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million. As a group, equities analysts expect that Harrow will post -0.53 EPS for the current fiscal year.

About Harrow

(Get Free Report

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Featured Articles

Analyst Recommendations for Harrow (NASDAQ:HROW)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Harrow Right Now?

Before you consider Harrow, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harrow wasn't on the list.

While Harrow currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Made in America Stocks Under $20 You Need to See!
3 Cheap Growth Stocks Set to Explode This Summer
The Next NVIDIA? Quantum Computing Stocks Set for Explosive Growth

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines